ACCESS Through OTC Innovation Act

This bill (HR 6868) streamlines the FDA review process for over-the-counter (OTC) drugs by requiring the agency to use the "least burdensome" approach when evaluating manufacturer requests to add new products to standardized OTC safety guidelines. It mandates that the FDA meet with companies if existing data is insufficient, provide written recommendations for necessary studies, and document these meetings in the public administrative record. The bill directly affects drug manufacturers seeking to market new OTC products, reducing review barriers without changing safety standards or altering the criteria for FDA approval. This focuses on improving efficiency in the regulatory process for OTC drug innovations.